{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:42:20Z","timestamp":1777513340451,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Local skin reactions are common during imiquimod treatment of actinic keratosis (AK). Cyclical application of imiquimod may improve tolerability while maintaining efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To assess the tolerability of imiquimod and clearance rate of AK lesions after imiquimod application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Imiquimod 5% cream was administered three times per week for 4 weeks followed by 4 weeks of rest (cycle 1) to AK lesions on the head. If AK lesions remained visible at the end of cycle 1, a second treatment cycle was instituted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fifty percent (30 of 60) of patients experienced complete clearance of AK lesions, and 75% (30 of 40) of patients experienced partial clearance of AK lesions after imiquimod treatment at the end of cycle 2. Moreover, 77% of patients who achieved complete clearance had no visible AK lesions 12 weeks post-treatment. Imiquimod was well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Imiquimod cycle therapy may be a safe and effective treatment option for AK lesions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2310\/7750.2008.07045","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T15:01:24Z","timestamp":1426086084000},"page":"97-101","source":"Crossref","is-referenced-by-count":11,"title":["Open-Label Study to Assess the Safety and Efficacy of Imiquimod 5% Cream Applied Once Daily Three Times per Week in Cycles for Treatment of Actinic Keratoses on the Head"],"prefix":"10.1177","volume":"12","author":[{"given":"Jason K.","family":"Rivers","sequence":"first","affiliation":[{"name":"From the Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC; Pacific Dermaesthetics, Vancouver, BC; North Bay Dermatology Centre, North Bay, ON; and Innovaderm Research, Inc., Montreal, QC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Les","family":"Rosoph","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC; Pacific Dermaesthetics, Vancouver, BC; North Bay Dermatology Centre, North Bay, ON; and Innovaderm Research, Inc., Montreal, QC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Provost","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC; Pacific Dermaesthetics, Vancouver, BC; North Bay Dermatology Centre, North Bay, ON; and Innovaderm Research, Inc., Montreal, QC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC; Pacific Dermaesthetics, Vancouver, BC; North Bay Dermatology Centre, North Bay, ON; and Innovaderm Research, Inc., Montreal, QC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2008,5,1]]},"reference":[{"key":"bibr1-7750.2008.07045","doi-asserted-by":"publisher","DOI":"10.1016\/S1085-5629(99)80003-0"},{"key":"bibr2-7750.2008.07045","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.103344"},{"key":"bibr3-7750.2008.07045","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1994.tb08544.x"},{"key":"bibr4-7750.2008.07045","doi-asserted-by":"publisher","DOI":"10.1046\/j.0366-077X.2003.05621.x"},{"key":"bibr5-7750.2008.07045","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405053301804"},{"key":"bibr6-7750.2008.07045","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.1.231"},{"key":"bibr7-7750.2008.07045","doi-asserted-by":"publisher","DOI":"10.1177\/120347540400800504"},{"key":"bibr8-7750.2008.07045","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2002.01151.x"},{"key":"bibr9-7750.2008.07045","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.107808"},{"key":"bibr10-7750.2008.07045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5070\/D34VW339W4","volume":"10","author":"Navi D","year":"2004","journal-title":"Dermatol Online J"},{"key":"bibr11-7750.2008.07045","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.12.010"},{"key":"bibr12-7750.2008.07045","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.4.467"},{"key":"bibr13-7750.2008.07045","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.02.022"},{"key":"bibr14-7750.2008.07045","doi-asserted-by":"publisher","DOI":"10.1097\/00042728-200506000-00008"},{"key":"bibr15-7750.2008.07045","unstructured":"Perras C. Imiquimod 5% cream for actinic keratosis. Issues Emerg Health Technol 2004;Sep:1\u20134."},{"key":"bibr16-7750.2008.07045","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-004-0465-4"},{"key":"bibr17-7750.2008.07045","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.126257"},{"key":"bibr18-7750.2008.07045","doi-asserted-by":"publisher","DOI":"10.1046\/j.0366-077X.2003.05629.x"},{"key":"bibr19-7750.2008.07045","first-page":"108","volume":"29","author":"Lang PG","year":"2003","journal-title":"Compr Ther"},{"key":"bibr20-7750.2008.07045","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.103339"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2310\/7750.2008.07045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.2310\/7750.2008.07045","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2310\/7750.2008.07045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:48:08Z","timestamp":1777391288000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2310\/7750.2008.07045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.2310\/7750.2008.07045"],"URL":"https:\/\/doi.org\/10.2310\/7750.2008.07045","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}